• Femasys partnered with CapexMD to offer dedicated patient financing for its FemaSeed-led fertility portfolio.
• Financing aims to broaden access to FemaSeed Complete, positioned as a lower-cost first-line option versus IVF.
• Program also covers FemVue and SpermVue diagnostics across OB/GYN practices and fertility centers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090900PRIMZONEFULLFEED9823728) on September 09, 2026, and is solely responsible for the information contained therein.